Animal models of urinary bladder cancer and their application to novel drug discovery

Bibliography

• Sexton WJ, Wiegand LR, Correa JJ, et al. Bladder cancer: a review of non-muscle invasive disease. Cancer Contr 2010;17:256–68
   PubMed Web of Science ®Google Scholar
• Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol 2008;7(Supp l7):618–26
   Google Scholar
• Wu X, Ros MM, Gu J, et al. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008;102:1207–15
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Sauter G, Gasser T, et al. Infiltrating urothelial carcinoma World Health Organization classification of tumours pathology and genetics of tumours of the urinary system and male genital system. IARC Press, Lyon, France; 2004. p. 93–109
   Google Scholar
• Lorenzo-Gómez MF, Padilla-Fernández B, Arcila-Piedrahita A, et al. Metastatic urothelial cancer of the bladder cancer presented for the first time in its final stage: case report and literature review. J Palliative Care Med 2012;2:122
   Google Scholar
• Chu H, Wang M, Zhang Z. Bladder cancer epidemiology and genetic susceptibility. J Biomed Res 2013;27:170–8
   PubMedGoogle Scholar
• Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 1999;12:97–111
   PubMed Web of Science ®Google Scholar
• Wirth M, Plattner VE, Gabor F. Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 2009;6:727–44
   PubMed Web of Science ®Google Scholar
• Eiján AM, Lodillinsky C, Sandes EO. Animal models for basic and preclinical research in bladder cancer. In: Canda A, editor, Bladder cancer - from basic science to robotic surgery. InTech, Croatia; 2012. p. 383-404; ISBN: 978-953-307-839-7
   Google Scholar
• Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552–64
   PubMed Web of Science ®Google Scholar
• Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;3:296–304
   Google Scholar
• Yang X, Flaig TW. Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol 2010;36:273–82
   PubMed Web of Science ®Google Scholar
• Smith K, Fennelly JA, Neal DE, et al. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 1989;49:5810–15
   PubMed Web of Science ®Google Scholar
• Tanaka MF, Sonpavde G. Diagnosis and management of urothelial carcinoma of the bladder. Postgrad Med 2011;123:43–55
   PubMed Web of Science ®Google Scholar
• Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565–72
   PubMed Web of Science ®Google Scholar
• van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429–34
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186–90
   PubMed Web of Science ®Google Scholar
• Ismaili N, Amzerin M, Flechon A. Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol 2011;4:35–45
   PubMed Web of Science ®Google Scholar
• Loehrer PJS, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066–73
   PubMed Web of Science ®Google Scholar
• Gabriel U, Bolenz C, Michel MS. Experimental models for therapeutic studies of transitional cell carcinoma. Anticancer Res 2007;27:3163–71
   PubMed Web of Science ®Google Scholar
• Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007;7:659–72
   PubMed Web of Science ®Google Scholar
• Varley CL, Southgate J. Organotypic and 3D reconstructed cultures of the human bladder and urinary tract. Methods Mol Biol 2011;695:197–211
   PubMedGoogle Scholar
• Wessler S. Introduction: what is a model? In: Animal models of thrombosis and hemorrhagic disease. National Institutes of Health, Bethesda; 1976. p. 11–16
   Google Scholar
• Reis LO, Pereira TC, Favaro WJ, et al. Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol 2009;27:353–61
   PubMed Web of Science ®Google Scholar
• Xiao Z, McCallum TJ, Brown KM, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 1999;81:638–46
   PubMed Web of Science ®Google Scholar
• Oliveira PA, Colaco A, De la Cruz PLF, et al. Experimental bladder carcinogenesis-rodent models. Exp Oncol 2006;28:2–11
   PubMedGoogle Scholar
• Arentsen HC, Hendricksen K, Oosterwijk E, et al. Experimental rat bladder urothelial cell carcinoma models. World J Urol 2009;27:313–17
   PubMed Web of Science ®Google Scholar
• Raghavan D, Debruyne F, Herr H, et al. Experimental models of bladder cancer: a critical review. In: Liss AR, editor, Developments in bladder cancer. Experimental models of bladder cancer: a critical review. New York; 1986. p. 171–208
   Google Scholar
• Gutiérrez JB, Salsamendi AL. Fundamientos de ciência toxicológica. Madrid, Diaz de Santos; 2001. p. 155–77
   Google Scholar
• Okajima E, Hiramatsu T, Hirao K, et al. Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in dogs. Cancer Res 1981;41:1958–66
   PubMed Web of Science ®Google Scholar
• Armstrong EC, Bonser GM. Epithelial tumours of the urinary bladder in mice induced by 2-acetylamino-fluorine. J Pathol 1944;6:506–12
   Google Scholar
• Lijinsky W. Species differences in nitrosamine carcinogenesis. J Cancer Res Clin Oncol 1984;108:46–55
   PubMed Web of Science ®Google Scholar
• Steinberg GD, Brendler CB, Ichikawa T, et al. Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res 1990;50:6668–74
   PubMed Web of Science ®Google Scholar
• Oliveira PA, Palmeira C, Lourenço L, et al. Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Exp Clin Cancer Res 2005;24:207–14
   Google Scholar
• Ito N, Shirai T, Fukushima S, et al. Dose-response study of urinary bladder carcinogenesis in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. J Cancer Res Clin Oncol 1984;108:169–73
   PubMed Web of Science ®Google Scholar
• Cohen SM, Friedell GH. Neoplasms of the urinary system. In: Foster HL, Small JD, Fox JG, editors, The mouse in biomedical research. Neoplasms of the urinary system. Academic Press, New York; 1982. p. 439–63
   Google Scholar
• Oliveira PA, Palmeira C, Colaco A, et al. DNA content analysis, expression of Ki-67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and Bacillus Calmette-Guerin. Anticancer Res 2006;26:2995–3004
   PubMed Web of Science ®Google Scholar
• Arantes-Rodrigues R, Colaço A, Pinto-Leite R, et al. In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer. Anticancer Res 2013;33:1273–96
   PubMed Web of Science ®Google Scholar
• Gil da Costa RM, Oliveira PA, Bastos MM, et al. Ptaquiloside-induced early-stage urothelial lesions show increased cell proliferation and intact beta-catenin and e-cadherin expression. Environ Toxicol 2012, doi:10.1002/tox.21803
   PubMed Web of Science ®Google Scholar
• Cohen SM. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 2002;30:663–71
   PubMed Web of Science ®Google Scholar
• Oliveira PA, Colaço A, de la Cruz PLF, et al. Rat and mouse urothelial carcinogenesis. Exp Pathol Health Sci 2008;2:23–8
   Google Scholar
• Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48
   PubMed Web of Science ®Google Scholar
• Boorman GA, Wood M, Fukushima S. Tumours of the urinary bladder. IARC Sci Publ 1994;111:383–406
   PubMedGoogle Scholar
• Dinney CP, Fishbeck R, Singh RK, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995;154:1532–8
   Google Scholar
• Steele VE, Lubet RA. The use of animal models for cancer chemoprevention drug development. Semin Oncol 2010;37:327–38
   PubMed Web of Science ®Google Scholar
• Rosenbert MP, Bortner D. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev 1998;17:295–9
   PubMed Web of Science ®Google Scholar
• Thomas H, Balkwill F. Assessing new anti-tumour agents and strategies in oncogene transfenic mice. Cancer Metastasis Rev 1995;14:91–5
   PubMed Web of Science ®Google Scholar
• Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005;11:6280–90
   PubMed Web of Science ®Google Scholar
• Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 2008;7:862–73
   PubMed Web of Science ®Google Scholar
• Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today 2012;17:253–60
   PubMed Web of Science ®Google Scholar
• Khleif NS, Curt GA. Animal models in developmental therapeutics. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, editors, Holland-frei cancer medicine. 5th edition. BC Decker, Hamilton; 2000
   Google Scholar
• Gunther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999;59:2834–7
   PubMed Web of Science ®Google Scholar
• Ibrahiem EH, Nigam VN, Brailovsky CA, et al. Orthotopic implantation of primary N-4-(5-Nitro-2-furyl)-2-thiazolyl] formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Cancer Res 1983;43:617–22
   PubMed Web of Science ®Google Scholar
• Oliveira PA, Pires MJ, Nóbrega C, et al. Technical report: technique of bladder catheterization in female mice and rats for intravesical instillation in models of bladder cancer. Scand J Lab Anim Sci 2009;36:5–9
   Web of Science ®Google Scholar
• Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599–602
   PubMed Web of Science ®Google Scholar
• Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 1970;24:746–54
   PubMed Web of Science ®Google Scholar
• Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 2014;87:150–61
   PubMed Web of Science ®Google Scholar
• Palmeira C, Oliveira PA, Lameiras C, et al. Biological similarities between murine chemical-induced and natural human bladder carcinogenesis. Oncol Lett 2010;1:373–7
   PubMed Web of Science ®Google Scholar
• Arantes-Rodrigues R, Pinto-Leite R, da Costa RG, et al. Cytogenetic characterization of an N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse papillary urothelial carcinoma. Tumour Biol 2013;34:2691–6
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu P, Wen W, et al. Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res 2010;3:8–27
   PubMedGoogle Scholar
• Yanagisawa T, Suzuki T, Kudoh T, et al. Effect of intravesical Bacillus Calmette-Guerin on N-butyl-N-(4-hydroxybutyl)-nitrosamine induced urinary bladder carcinogenesis in rats. Nihon Hinyokika Gakkai Zasshi 1994;85:945–52
   PubMedGoogle Scholar
• Tanaka S, Kudoh S, Mollik AU, et al. Histological study on intravesical instillation of Bacillus Calmette Guerin (BCG) and adriamycin for BBN induced bladder tumor in rats. Nihon Hinyokika Gakkai Zasshi 1992;83:368–73
   PubMedGoogle Scholar
• Steinberg GD, Brendler CB, Squire RA, et al. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model. J Urol 1991;145:647–53
   PubMed Web of Science ®Google Scholar
• Ohtani M, Fukushima S, Ito N, et al. Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats. Cancer Chemother Pharmacol 1983;11(Suppl):S64–6
   PubMedGoogle Scholar
• Miyazaki J, Nishiyama H, Yano I, et al. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res 2011;31:2065–71
   PubMed Web of Science ®Google Scholar
• Piazza GA, Thompson WJ, Pamukcu R, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001;61:3961–8
   PubMed Web of Science ®Google Scholar
• Lubet RA, Clapper ML, McCormick DL, et al. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncol Rep 2012;27:1400–6
   PubMed Web of Science ®Google Scholar
• Zhang G, Zeng X, Li C, et al. Inhibition of urinary bladder carcinogenesis by aqueous extract of sclerotia of Polyporus umbellatus fries and polyporus polysaccharide. Am J Chin Med 2011;39:135–44
   PubMed Web of Science ®Google Scholar
• Lubet RA, Steele VE, Juliana MM, et al. Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy. J Urol 2010;183:1598–603
   PubMed Web of Science ®Google Scholar
• Prasain JK, Jones K, Moore R, et al. Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers. Oncol Rep 2008;19:1565–70
   PubMed Web of Science ®Google Scholar
• Osawa S, Terashima Y, Kimura G, et al. Antitumour effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. BJU Int 1999;83:123–8
   PubMed Web of Science ®Google Scholar
• Szende B, Juhasz E, Lapis K, et al. Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Urol Res 1992;20:383–6
   PubMed Web of Science ®Google Scholar
• Thompson HJ, Becci PJ, Grubbs CJ, et al. Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice. Cancer Res 1981;41:933–6
   PubMed Web of Science ®Google Scholar
• Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998;58:3028–31
   PubMed Web of Science ®Google Scholar
• Yu A, Hashimura T, Nishio Y, et al. Anti-promoting effect of nordihydroguaiaretic acid on N-butyl-N-(4-hydroxybutyl)nitrosamine and sodium saccharin induced rat urinary bladder carcinogenesis. Jpn J Cancer Res 1992;83:944–8
   PubMedGoogle Scholar
• Okajima E, Ozono S, Endo T, et al. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl) nitrosamine treatment. Jpn J Cancer Res 1997;88:543–52
   PubMedGoogle Scholar
• Hattori K, Iida K, Joraku A, et al. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006;97:640–3
   PubMed Web of Science ®Google Scholar
• Okazaki K, Yamagishi M, Son HY, et al. Simultaneous treatment with benzyl isothiocyanate, a strong bladder promoter, inhibits rat urinary bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine. Nutr Cancer 2002;42:211–16
   PubMed Web of Science ®Google Scholar
• Masuda C, Wanibuchi H, Sekine K, et al. Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. Jpn J Cancer Res 2000;91:582–8
   PubMedGoogle Scholar
• Salim EI, Wanibuchi H, Morimura K, et al. Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 2000;21:195–203
   PubMed Web of Science ®Google Scholar
• Okajima E, Tsutsumi M, Ozono S, et al. Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation. Jpn J Cancer Res 1998;89:22–6
   PubMedGoogle Scholar
• Hirose Y, Tanaka T, Kawamori T, et al. Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats. Carcinogenesis 1995;16:2337–42
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin L, Takenaka I. MVAC chemotherapy-induced apoptosis and p53 alterations in the rat model of bladder cancer. Urology 1998;52:925–31
   PubMed Web of Science ®Google Scholar
• Parada B, Reis F, Figueiredo A, et al. Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int 2011;107:135–43
   PubMed Web of Science ®Google Scholar
• Babaya K, Takahashi S, Momose H, et al. Effects of single chemotherapeutic agents on development of urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats. Urol Res 1987;15:329–34
   PubMed Web of Science ®Google Scholar
• Parada B, Reis F, Cerejo R, et al. Omega-3 fatty acids inhibit tumor growth in a rat model of bladder cancer. Biomed Res Int 2013;2013:368178
   PubMed Web of Science ®Google Scholar
• Parada B, Reis F, Pinto A, et al. Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci 2012;13:8482–99
   PubMed Web of Science ®Google Scholar
• Sereno J, Parada B, Reis F, et al. Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. Mediators Inflamm 2010;2010:380937
   PubMedGoogle Scholar
• Parada B, Sereno J, Reis F, et al. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol Ther 2009;8:1615–22
   PubMed Web of Science ®Google Scholar
• Chihara Y, Fujimoto K, Miyake M, et al. Antitumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis. Oncol Rep 2009;22:23–8
   PubMed Web of Science ®Google Scholar
• Ihlaseh SM, de Oliveira ML, Teràn E, et al. Chemopreventive property of dietary ginger in rat urinary bladder chemical carcinogenesis. World J Urol 2006;24:591–6
   PubMed Web of Science ®Google Scholar
• Sato D, Matsushima M. Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 2003;10:160–6
   PubMed Web of Science ®Google Scholar
• Kawahara M, Matsuhashi T, Yagishita T, et al. Inhibition of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder tumor in rats by alpha-difluoromethylornithine. Hinyokika Kiyo 1987;33:27–30
   PubMedGoogle Scholar
• Dornelas CA, Fechine-Jamacaru FV, Albuquerque IL, et al. Angiogenesis inhibition by green propolis and the angiogenic effect of L-lysine on bladder cancer in rats. Acta Cir Bras 2012;27:529–36
   PubMed Web of Science ®Google Scholar
• Takei S, Iseda T, Yokoyama M. Inhibitory effect of clotrimazole on angiogenesis associated with bladder epithelium proliferation in rats. Int J Urol 2003;10:78–85
   PubMed Web of Science ®Google Scholar
• Wada S, Kinoshita Y, Kamizuru M, et al. A study of antitumor effects of thymosin on rat and mouse urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Oncol Res 1996;8:139–44
   PubMed Web of Science ®Google Scholar
• Fujita J, Tokuda H, Ito Y, et al. Therapeutic effect of a retinoid (Ro 10-9359) on rats with bladder tumours induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine upon administration alone or in combination with mitomycin C. Urol Res 1983;11:227–30
   PubMed Web of Science ®Google Scholar
• Reis LO, Ferreira U, Billis A, et al. Antiangiogenic effects of the superantigen staphylococcal enterotoxin B and Bacillus Calmette-Guerin immunotherapy for non muscle invasive bladder cancer. J Urol 2012;187:438–45
   PubMed Web of Science ®Google Scholar
• Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001;165:253–8
   PubMed Web of Science ®Google Scholar
• Kong C, Zhu Y, Sun C, et al. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 2005;65:395–9
   PubMed Web of Science ®Google Scholar
• Zeng J, Sun Y, Wu K, et al. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 2011;10:104–16
   PubMed Web of Science ®Google Scholar
• Ou TT, Wu CH, Hsu JD, et al. Paeonia lactiflora Pall inhibits bladder cancer growth involving phosphorylation of Chk2 in vitro and in vivo. J Ethnopharmacol 2011;135:162–72
   PubMed Web of Science ®Google Scholar
• Holmang S, Cano M, Grenabo L, et al. Effect of indomethacin on N-4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced urinary tract carcinogenesis. Carcinogenesis 1995;16:1493–8
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Nobrega C, Pinto-Leite R, Arantes-Rodrigues R, et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol 2013;31:1212–21
   PubMed Web of Science ®Google Scholar
• Oliveira PA, Arantes-Rodrigues R, Sousa-Diniz C, et al. The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Res 2009;29:3221–6
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Nobrega C, Colaco A, Santos L, et al. Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions. Anticancer Res 2011;31:1637–42
   PubMed Web of Science ®Google Scholar
• Tyagi A, Raina K, Singh RP, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007;6:3248–55
   PubMed Web of Science ®Google Scholar
• Arantes-Rodrigues R, Pinto-Leite R, Ferreira R, et al. Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer. Biomed Pharmacother 2013;67:277–84
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Miyamoto S, Suzuki R, et al. Dietary beta-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Oncol Rep 2007;17:297–304
   PubMed Web of Science ®Google Scholar
• Yang M, Tanaka T, Hirose Y, et al. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int J Cancer 1997;73:719–24
   PubMed Web of Science ®Google Scholar
• Tanaka T, Morishita Y, Suzui M, et al. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 1994;15:15–19
   PubMed Web of Science ®Google Scholar
• Ozawa A, Tanji N, Kikugawa T, et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 2010;105:1181–6
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Kohjimoto Y, Nishihata M, et al. Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines. Urology 2009;74:1370–6
   PubMed Web of Science ®Google Scholar
• George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 2013;6:244–55
   PubMed Web of Science ®Google Scholar
• Becci PJ, Thompson HJ, Grubbs CJ, et al. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 1978;38:4463–6
   PubMed Web of Science ®Google Scholar
• Lubet RA, Huebner K, Fong LY, et al. 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and surviving expression and chemopreventive effects of indomethacin. Carcinogenesis 2005;26:571–8
   PubMed Web of Science ®Google Scholar
• Rao KV, Detrisac CJ, Steele VE, et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435–8
   PubMed Web of Science ®Google Scholar
• Moon RC, Kelloff GJ, Detrisac CJ, et al. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994;14:5–11
   PubMed Web of Science ®Google Scholar
• D'Arca D, LeNoir J, Wildemore B, et al. Prevention of urinary bladder cancer in the FHIT knock-out mouse with rofecoxib, a Cox-2 inhibitor. Urol Oncol 2010;28:189–94
   PubMed Web of Science ®Google Scholar
• Chihara Y, Fujimoto K, Miyake M, et al. Antitumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis. Oncol Rep 2009;22:23–8
   PubMed Web of Science ®Google Scholar
• Bidinotto LT, Spinardi-Barbisan AL, Rocha NS, et al. Effects of ginger (Zingiber officinale Roscoe) on DNA damage and development of urothelial tumors in a mouse bladder carcinogenesis model. Environ Mol Mutagen 2006;47:624–30
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Gohji K, et al. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121–6
   PubMed Web of Science ®Google Scholar
• Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammine platinum-induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009;73:655–60
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391–9
   PubMed Web of Science ®Google Scholar
• Kassouf W, Luongo T, Brown G, et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006;176:787–92
   PubMed Web of Science ®Google Scholar
• Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279–90
   PubMed Web of Science ®Google Scholar
• Chiong E, Lee IL, Dadbin A, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011;17:2863–73
   PubMed Web of Science ®Google Scholar
• Sato K, Yuasa T, Nogawa M, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 2006;95:1354–61
   PubMed Web of Science ®Google Scholar
• Kosugi M, Miyajima A, Kikuchi E, et al. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell 2007;20:1–9
   PubMed Web of Science ®Google Scholar
• Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammine platinum-induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009;73:655–60
   PubMed Web of Science ®Google Scholar
• Ma Y, Yu WD, Trump DL, et al. 1,25D3 Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010;116:3294–303
   PubMed Web of Science ®Google Scholar
• Adhim Z, Matsuoka T, Bito T, et al. In vitro and in vivo inhibitory effect of three COX-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 2011;105:393–402
   PubMed Web of Science ®Google Scholar
• Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012;64:599–606
   PubMed Web of Science ®Google Scholar
• Bai Y, Mao QQ, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010;101:488–93
   PubMed Web of Science ®Google Scholar
• Smakman N, Schaap N, Snijckers CM, et al. NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation. Urology 2005;66:434–40
   PubMed Web of Science ®Google Scholar
• Okamoto A, Shirakawa T, Bito T, et al. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 2008;71:156–60
   PubMed Web of Science ®Google Scholar
• Mohammed SI, Dhawan D, Abraham S, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006;5:329–36
   PubMed Web of Science ®Google Scholar
• Azuma H, Takahara S, Horie S, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003;169:2372–7
   PubMed Web of Science ®Google Scholar
• Plissonnier ML, Fauconnet S, Bittard H, et al. The antidiabetic drug ciglitazone induces high-grade bladder cancer cell apoptosis through the up-regulation of TRAIL. PLoS One 2011;6:e28354
   PubMed Web of Science ®Google Scholar
• Singh RP, Tyagi A, Sharma G, et al. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008;14:300–8
   PubMed Web of Science ®Google Scholar
• Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003;2:65–72
   PubMed Web of Science ®Google Scholar
• Horinaga M, Fukuyama R, Iida M, et al. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology 2010;76(5):1267. e1-6
   PubMedGoogle Scholar
• Nativ O, Dalal E, Laufer M, et al. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology 2004;64:845–8
   PubMed Web of Science ®Google Scholar
• Yu DS, Lee CF, Hsieh DS, et al. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology 2004;63:596–601
   PubMed Web of Science ®Google Scholar
• Chan ES, Patel AR, Hansel DE, et al. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. Urology 2012;80:736.e1–5
   Web of Science ®Google Scholar
• Swellam T, Miyanaga N, Onozawa M, et al. Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol 2003;10:213–19
   PubMed Web of Science ®Google Scholar
• Liu H, Schwartz MJ, Hwang DH, et al. Tumour growth inhibition by an imidazoquinoline is associated with cMyc down-regulation in urothelial cell carcinoma. BJU Int 2008;101:894–901
   PubMed Web of Science ®Google Scholar
• Ikemoto S, Sugimura K, Kuratukuri K, et al. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2). Anticancer Res 2004;24:733–6
   PubMed Web of Science ®Google Scholar
• Ikemoto S, Sugimura K, Yoshida N, et al. Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 2000;55:951–5
   PubMed Web of Science ®Google Scholar
• Moon DG, Cheon J, Yoon DH, et al. Allium sativum potentiates suicide gene therapy for murine transitional cell carcinoma. Nutr Cancer 2000;38:98–105
   PubMed Web of Science ®Google Scholar
• Yang HJ, Yen MC, Lin CC, et al. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. Exp Biol Med 2010;235:869–76
   PubMed Web of Science ®Google Scholar
• Moltedo B, Faunes F, Haussmann D, et al. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins. J Urol 2006;176:2690–5
   PubMed Web of Science ®Google Scholar
• Kamat AM, Tharakan ST, Sung B, et al. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 2009;69:8958–66
   PubMed Web of Science ®Google Scholar
• Guais A, Baronzio G, Sanders E, et al. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs 2012;30:200–11
   PubMed Web of Science ®Google Scholar
• Schwartz L, Abolhassani M, Guais A, et al. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep 2010;23:1407–16
   PubMed Web of Science ®Google Scholar
• Lee KE, Iwamura M, Cockett AT. Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice. Cancer Chemother Pharmacol 1990;26:461–3
   PubMed Web of Science ®Google Scholar
• Selman SH, Keck RW. A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model. J Urol 2011;186:702–6
   PubMed Web of Science ®Google Scholar
• Abramjuk C, Bueschges M, Schnorr J, et al. Divergent effects of taurolidine as potential antineoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. Oncol Rep 2009;22:409–14
   PubMed Web of Science ®Google Scholar
• Xiao Z, Hanel E, Mak A, et al. Antitumor efficacy of intravesical BCG, gemcitabine, interferon-alpha and interleukin-2 as mono- or combination-therapy for bladder cancer in an orthotopic tumor model. Clin Med Insights Oncol 2011;5:315–23
   PubMedGoogle Scholar
• Bhattacharya A, Li Y, Geng F, et al. The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis 2012;33:394–8
   PubMed Web of Science ®Google Scholar
• Xiao Z, Mak A, Koch K, et al. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model. BJU Int 2013;112:E201–10
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Tang L, Li Y, et al. Inhibition of bladder cancer development by allyl isothiocyanate. Carcinogenesis 2010;31:281–6
   PubMed Web of Science ®Google Scholar
• Nativ O, Aronson M, Medalia O, et al. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 1997;70:297–301
   PubMed Web of Science ®Google Scholar
• Brocks CP, Buttner H, Bohle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol 2005;174:1115–18
   PubMed Web of Science ®Google Scholar
• Nativ O, Dalal E, Laufer M, et al. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology 2004;64:845–8
   PubMed Web of Science ®Google Scholar
• Watanabe FT, Chade DC, Reis ST, et al. Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model. Clinics (Sao Paulo) 2011;66:2121–4
   PubMed Web of Science ®Google Scholar
• Leite KR, Chade DC, Sanudo A, et al. Effects of curcumin in an orthotopic murine bladder tumor model. Int Braz J Urol 2009;35:599–606
   PubMed Web of Science ®Google Scholar
• Riemensberger J, Böhle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002;127:20–6
   PubMed Web of Science ®Google Scholar
• Hayashi T, Crain B, Corr M, et al. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol 2010;17:483–90
   PubMed Web of Science ®Google Scholar
• Mossberg AK, Hou Y, Svensson M, et al. HAMLET treatment delays bladder cancer development. J Urol 2010;183:1590–7
   PubMed Web of Science ®Google Scholar
• Shen CH, Shee JJ, Wu JY, et al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol 2010;160:2008–27
   PubMed Web of Science ®Google Scholar
• Zhou JR, Mukherjee P, Gugger ET, et al. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 1998;58:5231–8
   PubMed Web of Science ®Google Scholar